Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. 2019 Top Stories in Renal Cell Carcinoma: Axitinib Plus Pembrolizumab and Axitinib Plus Avelumab in the First-Line Treatment of mRCC
  2. Prognostic Role of Pretreatment-Derived Neutrophil-to-Lymphocyte Ratio in Urological Cancers
  3. A Pilot Study of Radiation Therapy Combined With Pembrolizumab in Metastatic RCC
  4. Prognostic Implications of Aquaporin 9 Expression in ccRCC
  5. Extracranial SBRT for Metastatic Lesions From RCC
  6. Impact of Patients' Gender on Efficacy of Immunotherapy in Patients With Metastatic Kidney Cancer
  7. Individualized Immune-Related Gene Signature Predicts Immune Status and Oncologic Outcomes in ccRCC
  8. Everolimus + Panobinostat Is Not Effective in Patients With Advanced ccRCC
  9. SBRT in Combination With Systemic Therapy for Metastatic RCC
  10. Improved Survival After Adding SBRT to TKI in mRCC

Elsewhere

Recently Updated